Injections deliver liquid medications, fluids, or nutrients directly into a person’s body. Different types of injections include intravenous, intramuscular, subcutaneous, intraosseous, and intradermal ...

As with the intravenous form, subcutaneous anifrolumab shows clinically meaningful benefits and favorable safety when added ...

Basel, 11 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced late-breaking data from the Phase III OCARINA II study. Study results demonstrate the effect of OCREVUS® (ocrelizumab) as an ...

Please provide your email address to receive an email when new articles are posted on . The intravenous and subcutaneous formulations of Remsima had comparable efficacy, safety and immunogenicity ...

CHICAGO — Administering the bispecific antibody amivantamab (Rybrevant) subcutaneously rather than intravenously in combination with lazertinib (Leclaza) not only reduces administration times but also ...

A phase 3 trial demonstrated shorter administration times with subcutaneous vs IV delivery of nivolumab with no significant difference in mRCC progression-free survival. Subcutaneous administration of ...

RAHWAY, N.J., March 27, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first data presentation from the pivotal 3475A-D77 Phase 3 ...

Clinicians have a range of options for treating patients with disease states that require the use of immunoglobulin (Ig). Traditionally, intravenous immunoglobulin (IVIG) administration has provided ...

Johnson & Johnson’s attempt to switch physicians from intravenous to subcutaneous Darzalex is almost complete. Having won FDA approval for Darzalex Faspro in May 2020, J&J has converted 85% of its U.S ...

The subcutaneous formulation of Opdivo Qvantig reduces administration time to three to five minutes, compared to 30 minutes for the IV version. This formulation offers increased convenience, ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be ...